Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas.
The cellular and molecular events that initiate and promote malignant glioma development are not completely understood. The treatment modalities designed to promote its demise are all ultimately ineffective, leading to disease progression. In this issue of the JCI, Kioi et al. demonstrate that vasculogenesis and angiogenesis potentially play distinct roles in the etiology of primary and recurrent malignant gliomas, suggesting that patient therapy should perhaps be tailored specifically against the predominant vasculature pathway at a given specific stage of gliomagenesis.
Greenfield
Jeffrey P
JP
Pediatric Brain Tumor Research and Children's Cancer and Blood Foundation Laboratories, Champalimaud Metastasis Programme, New York, New York, USA. jpgreenf@med.cornell.edu
Cobb
William S
WS
Lyden
David
D
D000818:Animals; D019380:Anti-HIV Agents; D057134:Antibodies, Neutralizing; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001596:Benzylamines; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D039481:CD11b Antigen / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects / Q000528:radiation effects; D054377:Chemokine CXCL12 / Q000037:antagonists & inhibitors / Q000378:metabolism; D000080027:Cyclams; D005909:Glioblastoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006571:Heterocyclic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009000:Monocytes / Q000378:metabolism / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000378:metabolism; D014183:Transplantation, Heterologous; D014916:Whole-Body Irradiation
D019380:Anti-HIV Agents; D057134:Antibodies, Neutralizing; D000970:Antineoplastic Agents; D001596:Benzylamines; D039481:CD11b Antigen; C527276:CXCR4 protein, human; C514936:CXCR4 protein, mouse; D054377:Chemokine CXCL12; C515256:Cxcl12 protein, mouse; D000080027:Cyclams; D006571:Heterocyclic Compounds; D051793:Hypoxia-Inducible Factor 1; C509295:ITGAM protein, human; D019718:Receptors, CXCR4; C088327:plerixafor